secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inozyme Pharma, Inc. (—)
CIK:        0001693011
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0000950170-24-053979
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inozyme Pharma Q1 net loss $23.3M ($0.38/sh); cash $166.2M; positive ABCC6 data
-------------------------------------------------------------------------------

- Net loss $23.3M ($0.38 loss per share) vs $17.4M ($0.40) year ago.
- Cash, cash equivalents, and short-term investments $166.2M as of March 31, 2024; expected to fund operations into Q4 2025.
- Positive topline safety, immunogenicity, and clinical improvement data for INZ-701 in adults with ABCC6 Deficiency reported in April 2024.
- Plan to initiate pivotal trial in pediatric ABCC6 Deficiency in Q1 2025, subject to regulatory review and funding.
- Interim data from SEAPORT-1 (calciphylaxis) on track for Q4 2024; ENERGY-1 (ENPP1 infants) interim data expected 2H 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1693011/000095017024053979/0000950170-24-053979-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1693011/000095017024053979/inzy-20240507.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-053979

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer